Scholarly article on topic 'Ameloblastoma'

Ameloblastoma Academic research paper on "Clinical medicine"

Share paper
OECD Field of science

Academic research paper on topic "Ameloblastoma"

ental Science - Review Article


K. M. K. Masthan, N. Anitha, Jayasri Krupaa, Sudha Manikkam

Department of Oral Pathology and Microbiology, Sree Balaji Dental College and Hospitals, Bharath University, Chennai, Tamil Nadu, India

Address for correspondence:

Dr. Sudha Manikkam, E-mail: sudha.umashankar@


Ameloblastoma is a benign odontogenic tumor generally present in the jaw bone. The tumor originates from the residual epithelium of the tooth germ, epithelium of odontogenic cysts stratified squamous epithelium and epithelium of the enamel organ. It represents approximately 1% of oral tumors. About 80% of ameloblastomas occur in the mandible mainly the third molar region and the remaining 20% in the upper jaw. Ameloblastoma clinically appears as an aggressive odontogenic tumor, often asymptomatic and slow-growing, with no evidence of swelling. This article deals with a complete review on ameloblastoma.

Received : 31-10-14

Review completed : 31-10-14 Accepted : 09-11-14

KEY WORDS: Ameloblastoma, mandible, odontogenic

meloblastoma is a neoplasm of odontogenic epithelium, zjQf' principally of enamel organ-type tissue that has not undergone differentiation to the point of hard tissue formation.[1] It accounts for about 1% of all oral tumors and about 9-11% of odontogenic tumors. It is generally a slow-growing but locally invasive tumor.[2] Its peak incidence is in the third to fourth decades of life and the male: Female ratio is 1:1. Its incidence was 0.6 cases/million, and of 0.31 cases/million in a white population of South Africa.[3,4] Ameloblastoma accounted for 60.3% of all odontogenic tumors in Indian population, with a mean age of presentation of 30.2 years. A slight male predilection and major occurrence in the mandibular molar-ramus area were elicited.[5] They are classified as unicystic, multicystic or solid, 86% of cases are multicystic ameloblastomas. Ameloblastoma in the mandible can progress to great size and cause facial asymmetry, displacement of teeth, malocclusion, and pathologic fractures.

Access this article online

Quick Response Code: Website:

DOI: 10.4103/0975-7406.155891


Ameloblastoma, is derived from the English word "amel" which means enamel and the Greek word "blastos" which means the germ.[6] It arises from the epithelium of the dental lamina, and it is characterized by its local aggressive behavior and a high recurrence rate. Ameloblastoma was first described in 1827 by Cusack.[7] In 1885, Malassez introduced the name "adamantinoma," which is presently used to illustrate a rare form of bone cancer described by Fisher in 1913.[8] It was first detailed and described by Falkson in 1879. The term ameloblastoma was coined by Ivey and Churchill in 1930,[9,10] a currently accepted term. It is considered as a true neoplasm as the name implies it mimics the cells of the enamel-forming organ. It was described by Robinson in 1937, as a benign tumor that is "usually unicentric, nonfunctional, intermittent in growth, anatomically benign and clinically persistent." The World Health Organization (WHO) (1991) defined ameloblastoma as a benign but locally aggressive tumor with a high tendency to recur, consisting of proliferating odontogenic epithelium lying in a fibrous stroma.[11]


Ameloblastoma is classified, according to WHO and the International Agency for Research on Cancer, 2003, as a benign

How to cite this article: Masthan K, Anitha N, Krupaa J, Manikkam S. Ameloblastoma. J Pharm Bioall Sci 2015;7:S167-70.

tumor with odontogenic epithelium, mature fibrous stroma and without odontogenic ectomesenchyme. Ameloblastoma is further classified into:

• Solid/multicystic

• Extraosseous/peripheral

• Desmoplastic ameloblastoma

• Unicystic.

Solid/Multicystic Ameloblastoma

The solid or multicystic ameloblastoma is a benign epithelial odontogenic tumor of the jaws.[1] It is slow-growing locally aggressive and accounts for about 10% of all odontogenic tumors in the jaw.[12] Solid multicystic ameloblastoma (SMA) occur as growths arising from remnants of odontogenic epithelium, exclusively from rests of the dental lamina. SMAs may also arise as a result of neoplastic changes in the lining or wall of a nonneoplastic odontogenic cyst, in particular dentigerous and odontogenic keratocysts.[13] Signaling pathway such as WNT, Akt and growth factors like fibroblast growth factor play a pivotal role in the pathogenesis of solid type of ameloblastoma. Proteins mainly bone morphogenic protein ameloblastin, enamel matrix proteins calretinin, syndecan-1 and matrix metalloproteinases also play an important contribution in the etiopathogenesis. Tumor suppressor genes p53, p63 and p73 bring about molecular changes in the pathogenesis of ameloblastoma. p53 plays an important role in the differentiation and proliferation of odontogenic epithelial cells. Matrix metalloproteinases, triggers mitogens to be released, leading to the proliferation of ameloblastoma cells.[14]

Mostly this type is diagnosed in young adults, with a median age of 35 years and no gender predilection. About 80% of ameloblastomas occurs in the mandible,[2] frequently in the posterior region.[12] The lesions more often progresses slowly, but are locally invasive and infiltrates through the medullary spaces and erodes cortical bone. If left untreated, they resorb the cortical plate and extend into adjacent tissue. Crepitation or eggshell crackling might be elicited posterior maxillary tumors might obliterate the maxillary sinus and consequently extend intracranial.'151

Radiographically SMAs show an expansile, radiolucent, multiloculated cystic lesion, with a characteristic "soap bubble-like" appearance. Other findings include cystic areas of low attenuation with scattered regions representing soft tissue components. Thinning and expansion of the cortical plate with erosion through the cortex is elicited, with the associated unerupted tooth displaced and resorption of the roots of adjacent teeth common.'16

Six histopathologic subtypes of solid ameloblastoma includes follicular, plexiform, acanthomatous, basal cell, granular and DA. Mixtures of different histological patterns are commonly observed, and the lesions are frequently classified based on the predominant pattern present. The follicular pattern type has the highest recurrence rate of 29.5% and acanthomatous type having the least recurrence rate of 4.5%, and the rate of

recurrence depends on the histologic subtypes. The epithelial component of the neoplasm proliferates in the form of Islands, strands and cords within the moderately to densely collagenized connective tissue stroma. A prominent budding growth pattern with small, rounded extensions of epithelium projecting from larger islands, recapitulates the various stages of enamel organ formation. The classical histological pattern of ameloblastoma described by Vickers and Gorlin is characterized by peripheral layer of tall columnar cells with hyperchromasia, reverse polarity of the nuclei and sub-nuclear vacuole formation.'17!

Follicular type is composed of many small islands of peripheral layer of cuboidal or columnar calls with reversely polarized nucleus. Cyst formation is relatively common in follicular type. The term plexiform refers to the appearance of anastomosing islands of odontogenic epithelium, with double rows of columnar cells in back to back arrangement. In acanthomatous type, the cells occupying the position of stellate reticulum undergo squamous metaplasia, with keratin pearl formation in the center of tumor islands. In granular cell ameloblastoma, cytoplasm of stellate reticulum-like cells appear coarse granular and eosinophilic. Basal cell type, the epithelial tumor cells are less columnar and arranged in sheets. Desmoplastic variant is composed of the dense collagen stroma, which appears hypocellular and hyalinized.'17]

Other histological types are papilliferous-keratotic type, clear cell type, and mucous cell differentiation type. SMAs contain clear, periodic-acid Schiff positive cells most often localized to the stellate reticulum-like areas of follicular SMA.'13] Keratoameloblastoma consists partly of keratinizing cysts and partly of tumor islands with papilliferous appearance. Mucous cell type of ameloblastoma shows focal mucous cell differentiation, with vacuolated mucous cells.'18]

The main modality of treatment is surgery, with wide resection recommended due to the high recurrence rate of solid/multicystic ameloblastomas. The recurrence rate after resection is 13-15%, as opposed to 90-100% after curettage.'19' Recommend a margin of 1.5-2 cm beyond the radiological limit is implicated to ensure all microcysts are removed.'20'

Peripheral Ameloblastoma

The peripheral ameloblastoma (PA) is defined as an ameloblastoma that is confined to the gingival or alveolar mucosa. It infiltrates the surrounding tissues, mostly the gingival connective tissue, but it does not involve the underlying bone.'21] The PA arises from remnants of the dental lamina, the so-called "glands of Serres," odontogenic remnants of the vestibular lamina, pluripotent cells in the basal cell layer of the mucosal epithelium and pluripotent cells from minor salivary glands.'22'

The PA is an exophytic growth restricted to the soft tissues overlying the tooth-bearing areas of the jaws, the initial diagnosis often mistaken for fibrous epulis. In the majority of cases, there is no radiological evidence of bone involvement, but a superficial bone erosion known as cupping or saucerization may be detected

at surgery. The overall average age is 52.1 years, slightly higher for males than for females. The male/female ratio is 1.9 : 1, as opposed to 1.2 : 1 for the solid type. The maxilla/mandible ratio is 1 : 2.6. The mandibular premolar region accounts for 32.6% and is the commonest site.[23] Histologically same patterns are as in solid type, with a common type being acanthomatous.[17] Differential includes peripheral reactive lesions such as pyogenic granuloma, epulis, papilloma, fibroma, peripheral giant-cell granuloma, peripheral odontogenic fibroma, peripheral-ossifying fibroma, Baden's odontogenic gingival epithelial hamartoma, and basal cell carcinoma.[23]

The PA is mostly treated with a wide local excision. 9% of recurrence following treatment has been reported, though malignant transformation is rare, metastasis has also been reported.!24-25]

Desmoplastic Ameloblastoma

Desmoplastic ameloblastoma was first reported by Eversole et al. in 1984 and was recently included in the WHO's classification of head and neck tumors (WHO-2005).[26] This tumor is characterized by an unusual histomorphology, including extensive stromal collagenization or desmoplasia, leading to the proposed term ameloblastoma with pronounced desmoplasia or DA.[27]

Radiographically it produces mixed radiolucent - radioopaque lesion with diffuse border that indicates that the tumor is more aggressive than other variants of ameloblastoma.[28] Mixed radiologic appearance expresses the infiltrative pattern of the tumor and when the DA infiltrates the bone marrow spaces, remnants of the original nonmetaplastic or nonneoplastic bone were found to remain in the tumor tissue. The infiltrative behavior of the DA explains one of the characteristic features of the tumor, the ill-defined border.[13]

The DA also appears as a poorly defined, mixed, radiolucent-radiopaque lesion mimicking a benign fibro-osseous lesion, especially when evaluating panoramic and periapical radiographs.[29,30] Histologically DA appears as irregularly shaped odontogenic epithelial islands surrounded by a narrow zone of loose-structured connective tissue embedded in desmoplastic stroma.[31]

About 15.9% rate of recurrence has been reported in DA cases treated by enucleation and/or curettage, with an average recurrence period of 36.9 months.[29] The majority of DA cases reported treated by resection, most likely due to ill-defined borders, consequently suggesting an infiltration process and aggressive biological behavior.[32]

Unicystic Ameloblastoma

Unicystic ameloblastoma (UA) represents an ameloblastoma variant, presenting as a cyst that show clinical and radiologic characteristics of an odontogenic cyst. In histologic examination shows a typical ameloblastomatous epithelium lining part of

the cyst cavity, with or without luminal and/or mural tumor proliferation. In 1977, Robinson and Martinez first used the term "UA,[33]" but it was also named in the second edition of the international histologic classification of odontogenic tumors by the WHO as "cystogenic ameloblastoma." 5-15% of all ameloblastomas are of the unicystic type.[15]

Five to 15% of all ameloblastomas are of the unicystic type. UA with an unerupted tooth occurs with a mean age of 16 years as opposed to 35 years in the absence of an unerupted tooth. The mean age is considerably lower than that for solid/multicystic ameloblastoma with no gender predilection.[15] UA is a prognostically distinct entity with a recurrence rate of 6.7-35.7%, and the average interval for recurrence is approximately 7 years.

Three pathogenic mechanisms for the evolution of UA: Reduced enamel epithelium, from dentigerous cyst and due to cystic degeneration of solid ameloblastoma.[34]

Six radiographic patterns are identified for UA, ranging from well-defined unilocular to multilocular ones. Comparing unilocular and multilocular variants, there is an apparent predominance of a unilocular configuration in all studies of UA, especially in cases associated with impacted teeth.[35] UA might mimic other odontogenic cysts clinically and radiographically.

Histopathological classification of UAs are:[36]

• Luminal UA

• Luminal and intraluminal UAs

• Luminal, intraluminal, and intramural UAs

• Luminal and intramural UAs.

Treatment of UA includes both radical and conservative surgical excision, curettage, chemical and electrocautery, radiation therapy or combination of surgery and radiation.


The ameloblastoma is usually of late diagnosis because of its poor symptoms and low prevalence. Its treatment preferably includes the resection with safety margins and immediate reconstruction whenever possible. Routine histological classification of the ameloblastoma is mandatory for its morphological characterization and, thus, a better treatment definition. The main success factor associated with the treatment is the early diagnosis and to correlate the histopathologic findings with clinical and radiographic features to achieve at a correct definitive diagnosis as all such lesions might have prognostically different biologic behaviors and the final diagnosis may alter the therapeutic decision significantly.


1. Nakamura N, Mitsuyasu T, Higuchi Y, Sandra F, Ohishi M. Growth characteristics of ameloblastoma involving the inferior alveolar nerve: A clinical and histopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001:91:557-62.

2. Becelli R, Carboni A, Cerulli G, Perugini M, lannetti G. Mandibular ameloblastoma: Analysis of surgical treatment carried out

in 60 patients between 1977 and 1998. J Craniofac Surg 2002;13:395-400.

3. Larsson A, Almeren H. Ameloblastoma of the jaws. An analysis of a consecutive series of all cases reported to the Swedish Cancer Registry during 1958-1971. Acta Pathol Microbiol Scand A 1978;86A: 337-49.

4. Shear M, Singh S. Age-standardized incidence rates of ameloblastoma and dentigerous cyst on the Witwatersrand, South Africa. Community Dent Oral Epidemiol 1978;6:195-9.

5. Krishnapillai R, Angadi PV A clinical, radiographic, and histologic review of 73 cases of ameloblastoma in an Indian population. Quintessence Int 2010;41:e90-100.

6. Brazis PW, Miller NR, Lee AG, Holliday MJ. Neuro-ophthalmologic Aspects of Ameloblastoma. Skull Base Surg 1995;5:233-44.

7. Cusack JW. Report of the amputations of the lower jaw. Dubl Hosp Rec 1827;4:1-38.

8. Malassez L. The role of debris on EPITHELIAL papdentaires. Arch Physiol Norm Pathol 1885;5:309-40, 6:379-449.

9. Cakur B, Caglayan F, Altun O, Miloglu O. Plexiform ameloblastoma. Erciyes Med J 2009;Suppl 1:S62-7.

10. Madhup R, Srivastava K, Bhatt M, Srivastava S, Singh S, Srivastava AN. Giant ameloblastoma of jaw successfully treated by radiotherapy. Oral Oncol Extra 2006;42:22-5.

11. Kramer IR, Pindborg JJ, Shear M. Histological Typing of Odontogenic Tumours. WHO International Histological Classification of Tumours. 2nd ed. Berlin: Springer-Verlag; 1992. p. 11-14.

12. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NF! Ameloblastoma. Am J Clin Oncol 2007;30:645-8.

13. Peter AR, Philipsen HA. Odontogenic Tumors and Allied Lesions. 1st ed. London: Quintessence; 2004. p. 43-58.

14. Jeddy N, Jeyapradha T, Ananthalakshmi R, Jeeva S, Saikrishna P Lakshmipathy P The molecular and genetic aspects in the pathogenesis and treatment of ameloblastoma. J Dr NTR Univ Health Sci 2013;2:157-61.

15. Barnes L, Eveson JW, Reichart P Sidransky D, editors. World Health Organization Classification of Tumours: Head and Neck Tumours. Lyon, France: IARC Press; 2005.

16. Dunfee BL, Sakai O, Pistey R, Gohel A. Radiologic and pathologic characteristics of benign and malignant lesions of the mandible. Radiographics 2006;26:1751-68.

17. Rajendran R. Cyst and tumors of odontogenic origin. In: Rajendran R, Sivapathasundharam B, editors. Shafer's Text Book of Oral Pathology. 7th ed. Noida: Elsevier; 2012. p. 259-313.

18. Pindborg JJ. Odontog enic tumors. In: Pathology of the Dental Hard Tissue. Copen Hagen: Munksgaard; 1970. p. 367-428.

19. Chapelle KA, Stoelinga PJ, de Wilde PC, Brouns JJ, Voorsmit RA. Rational approach to diagnosis and treatment of ameloblastomas and odontogenic keratocysts. Br J Oral Maxillofac Surg 2004;42:381-90.

20. Hong J, Yun PY, Chung IH, Myoung H, Suh JD, Seo BM, et al. Long-term follow up on recurrence of 305 ameloblastoma cases. Int J Oral Maxillofac Surg 2007;36:283-8.

21. Gardner DG, Corio RL. Plexiform unicystic ameloblastoma. A variant of ameloblastoma with a low-recurrence rate after enucleation. Cancer 1984;53:1730-5.

22. Isomura ET, Okura M, Ishimoto S, Yamada C, Ono Y, Kishino M, et al. Case report of extragingival peripheral ameloblastoma in buccal mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:577-9.

23. Philipsen HP Reichart PA, Nikai H, Takata T, Kudo Y. Peripheral ameloblastoma: Biological profile based on 160 cases from the literature. Oral Oncol 2001;37:17-27.

24. Buchner A, Sciubba JJ. Peripheral epithelial odontogenic tumors: A review. Oral Surg Oral Med Oral Pathol 1987;63:688-97.

25. Lin SC, Lieu CM, Hahn LJ, Kwan HW. Peripheral ameloblastoma with metastasis. Int J Oral Maxillofac Surg 1987;16:202-4.

26. Eversole LR, Leider AS, Hansen LS. Ameloblastomas with pronounced desmoplasia. J Oral Maxillofac Surg 1984;42:735-40.

27. Reichart PA, Philipsen HA. Desmoplastic Ameloblastoma: Odontogenic Tumors and Allied Lesions. London: Quintessence Publishing Co Ltd.; 2004. p. 69-76.

28. Mintz S, Velez I. Desmoplastic variant of ameloblastoma: Report of two cases and review of the literature. J Am Dent Assoc 2002;133:1072-5.

29. Sun ZJ, Wu YR, Cheng N, Zwahlen RA, Zhao YF Desmoplastic ameloblastoma - A review. Oral Oncol 2009;45:752-9.

30. Manuel S, Simon D, Rajendran R, Naik BR. Desmoplastic ameloblastoma: A case report. J Oral Maxillofac Surg 2002;60:1186-8.

31. Philipsen HP, Reichart PA, Takata T. Desmoplastic ameloblastoma (including "hybrid" lesion of ameloblastoma). Biological profile based on 100 cases from the literature and own files. Oral Oncol 2001;37:455-60.

32. Ng KH, Siar CH. Desmoplastic variant of ameloblastoma in Malaysians. Br J Oral Maxillofac Surg 1993;31:299-303.

33. Robinson L, Martinez MG. Unicystic ameloblastoma: A prognostically distinct entity. Cancer 1977;40:2278-85.

34. Robert EM, Diane S. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. Chicago, Ill, USA: Quintessence; 2003.

35. Eversole LR, Leider AS, Strub D. Radiographic characteristics of cystogenic ameloblastoma. Oral Surg Oral Med Oral Pathol 1984;57:572-7.

36. Philipsen HP Reichart PA. Unicystic ameloblastoma. A review of 193 cases from the literature. Oral Oncol 1998;34:317-25.

Source of Support: Nil, Conflict of Interest: None declared.

Copyright of Journal of Pharmacy & Bioallied Sciences is the property of Medknow Publications & Media Pvt. Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.